Urinalysis Test Market

Urinary Tract Infections are becoming more common to boost the market growth. Governments also implement screening initiatives to diagnose illnesses like renal and urinary disorders early. For instance, 12,497 students from primary and secondary schools in Pingyang, Cangnan, and Yongjia in Wenzhou, China, were screened for urinalysis under school urinary analysis programs. The detection rate for urine abnormalities was 36% in primary and 95% in secondary school students. The demand for urinalysis tests is anticipated to increase as these programs increase.

The segment's growth is influenced by increased investment in creating urine testing kits for use at home to diagnose diseases. For instance, Vivoo raised USD 6 million in November 2021 to develop at-home urine tests that offer dietary and lifestyle recommendations. Developing nations with high price sensitivity favored inexpensive but equally functional analyzers for routine urinalysis tests. Therefore, creating inexpensive urinalysis tests is anticipated to drive market expansion and has enhanced the Urinalysis Test market CAGR across the globe in recent years.

The global increase in the geriatric population is a critical factor influencing the Global Urinalysis Test Market Industry. Older adults are more susceptible to various health conditions, including urinary tract infections and chronic kidney diseases, which necessitate regular urinalysis for effective management. According to demographic studies, the proportion of individuals aged 65 and older is expected to rise significantly, thereby increasing the demand for diagnostic tests. This demographic shift underscores the need for accessible and reliable urinalysis solutions, positioning the market for continued expansion as healthcare systems adapt to cater to an aging population.

The expansion of healthcare infrastructure in developing regions is fostering growth in the Global Urinalysis Test Market Industry. As countries invest in improving healthcare facilities and access to diagnostic services, the availability of urinalysis tests is increasing. This expansion is particularly evident in regions where healthcare systems are evolving to meet the demands of growing populations. Enhanced access to urinalysis testing not only improves patient outcomes but also encourages routine screenings, thereby driving market growth. The ongoing development of healthcare infrastructure is expected to play a pivotal role in shaping the future landscape of the urinalysis market.

The increasing incidence of urinary disorders globally drives the Global Urinalysis Test Market Industry. Conditions such as urinary tract infections and kidney diseases are becoming more prevalent, necessitating regular urinalysis for diagnosis and monitoring. For instance, the World Health Organization indicates that urinary tract infections affect millions worldwide, leading to a heightened demand for urinalysis tests. This trend is expected to contribute significantly to the market's growth, with projections estimating the market to reach 2.89 USD Billion in 2024 and potentially 6.42 USD Billion by 2035, reflecting a robust CAGR of 7.52% from 2025 to 2035.

The rising awareness of preventive healthcare among populations globally is a significant driver for the Global Urinalysis Test Market Industry. Individuals are increasingly recognizing the importance of regular health screenings, including urinalysis, to detect potential health issues early. This trend is particularly evident in developed nations where health education campaigns emphasize the benefits of preventive measures. Consequently, healthcare providers are incorporating routine urinalysis into standard check-ups, leading to a surge in demand for these tests. This shift towards preventive healthcare is likely to sustain market growth in the coming years.

Technological innovations in diagnostic tools are propelling the Global Urinalysis Test Market Industry forward. The introduction of automated urinalysis systems and point-of-care testing devices enhances the efficiency and accuracy of urinalysis. These advancements facilitate quicker results, which are crucial for timely medical interventions. For example, the integration of artificial intelligence in urinalysis systems allows for improved interpretation of results, thereby increasing diagnostic reliability. As healthcare providers increasingly adopt these advanced technologies, the market is poised for substantial growth, aligning with the projected increase in market value.

By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America Urinalysis Test market accounted for USD 1.145 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. This dominance can be attributed to strategic actions taken by important players, like licensing agreements to increase business footprint. For instance, Sysmex and Siemens Healthcare GmbH signed an exclusive licensing agreement in 2020 to distribute and support the automated urine analyzer CLINITEK Novus to North America's hospitals and reference laboratories.

The market will grow as a result of this agreement.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: URINALYSIS TEST MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe’s Urinalysis Test market accounts for the second-largest market share due to the availability of cutting-edge treatment facilities, government backing for the growth of the healthcare industry, an aging population, and an increase in the incidence of degenerative disc disease, rheumatoid arthritis, and osteoarthritis. Further, the Germany Urinalysis Test market held the largest market share, and the UK Urinalysis Test market was the fastest-growing market in the European region.

The Asia-Pacific Urinalysis Test Market is expected to grow at the fastest CAGR from 2022 to 2030. VSI Electronics Pvt. Ltd. and other domestic urine analyzer producers. Some key elements driving the regional market growth are the presence of a sizable patient base with unmet clinical needs, the increasing adoption of advanced urine analyses, Ltd. and Medical Equipment India, and these three factors combined. Moreover, China’s Urinalysis Test market held the largest market share, and the India Urinalysis Test market was the fastest-growing market in the Asia-Pacific region.

Major market players are spending much money on R&D to increase their product lines, which will help the Urinalysis Test market grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Urinalysis Test industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies manufacturers adopt in the Global Urinalysis Test industry to benefit clients and expand the market sector is manufacturing locally to reduce operating costs. The Urinalysis Test industry has provided medicine with some of the most significant benefits in recent years. The Urinalysis Test markets major players such as ACON Laboratories (US), Siemens Healthineers (Germany), URIT Medical Electronic Ltd (China), Roche Diagnostics (Switzerland), Beckman Coulter (US), Sysmex Corporation (Japan), DIRUI (China), Arkray Inc. (Japan),77 Elektronika Kft (Hungary) and others are working on expanding the market demand by investing in research and development activities.

DIRUI (China) With ongoing research and development, DIRUI began manufacturing urine strips in 1992. Today, the company's product portfolio includes 8 product lines for biochemistry, urinalysis, hematology, chemiluminescence immunoassay, gynecology, and blood coagulation analysis. Future predictions include the emergence of new disciplines like spectrometry and POCT. We offer customized laboratory solutions that can satisfy different customer needs. In more than 120 countries and regions, hospitals, reference labs, and other medical facilities use DIRUI diagnostic systems. All of DIRUI's products are CE certified, and some of them also hold FDA certification.

The company is an ISO 13485 and ISO 9001 certified manufacturer. In the international IVD market, DIRUI has successfully built a solid reputation. DIRUI provides the best platform for all employees and partners thanks to its top-notch manufacturing, research, and development capabilities. Currently, 1,700 of us are working toward a common objective: to become a premier provider of complete laboratory solutions, supporting human healthcare, enhancing life quality, and maximizing benefits for all.

Also, Beckman Coulter (US), leading the way globally in clinical diagnostics, Beckman Coulter Diagnostics has pushed the boundaries for more than 80 years to elevate the diagnostic laboratory's contribution to patient health. Our team's passion and creativity, along with the power of science and technology, are used to reimagine healthcare, one diagnosis at a time relentlessly. Our diagnostic solutions are used in intricate clinical testing in hospitals, reference labs, and doctor's offices worldwide. We are here to provide better, quicker diagnostic solutions that help us move from the present to the future.

We accelerate care by utilizing a broad clinical menu, scalable lab automation technologies, insightful clinical informatics, and lab performance optimization services.